AU2018264384B2 - Solid forms of berberine ursodeoxycholate and compositions and methods thereof - Google Patents

Solid forms of berberine ursodeoxycholate and compositions and methods thereof Download PDF

Info

Publication number
AU2018264384B2
AU2018264384B2 AU2018264384A AU2018264384A AU2018264384B2 AU 2018264384 B2 AU2018264384 B2 AU 2018264384B2 AU 2018264384 A AU2018264384 A AU 2018264384A AU 2018264384 A AU2018264384 A AU 2018264384A AU 2018264384 B2 AU2018264384 B2 AU 2018264384B2
Authority
AU
Australia
Prior art keywords
bbr
udca
xrpd
certain embodiments
berberine ursodeoxycholate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018264384A
Other languages
English (en)
Other versions
AU2018264384A1 (en
Inventor
Xinxiang FU
Liping Liu
Meng YU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Hightide Biopharmaceutical Ltd
Original Assignee
Shenzhen Hightide Biopharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Hightide Biopharmaceutical Ltd filed Critical Shenzhen Hightide Biopharmaceutical Ltd
Publication of AU2018264384A1 publication Critical patent/AU2018264384A1/en
Application granted granted Critical
Publication of AU2018264384B2 publication Critical patent/AU2018264384B2/en
Priority to AU2022206685A priority Critical patent/AU2022206685B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2018264384A 2017-05-12 2018-05-11 Solid forms of berberine ursodeoxycholate and compositions and methods thereof Active AU2018264384B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022206685A AU2022206685B2 (en) 2017-05-12 2022-07-18 Solid forms of berberine ursodeoxycholate and compositions and methods thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710335467.5A CN108864077B (zh) 2017-05-12 2017-05-12 小檗碱有机酸盐的固体形式及其制备方法
CN201710335467.5 2017-05-12
PCT/CN2018/086461 WO2018205987A1 (en) 2017-05-12 2018-05-11 Solid forms of berberine ursodeoxycholate and compositions and methods thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022206685A Division AU2022206685B2 (en) 2017-05-12 2022-07-18 Solid forms of berberine ursodeoxycholate and compositions and methods thereof

Publications (2)

Publication Number Publication Date
AU2018264384A1 AU2018264384A1 (en) 2019-12-12
AU2018264384B2 true AU2018264384B2 (en) 2022-05-19

Family

ID=64105207

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018264384A Active AU2018264384B2 (en) 2017-05-12 2018-05-11 Solid forms of berberine ursodeoxycholate and compositions and methods thereof
AU2022206685A Active AU2022206685B2 (en) 2017-05-12 2022-07-18 Solid forms of berberine ursodeoxycholate and compositions and methods thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022206685A Active AU2022206685B2 (en) 2017-05-12 2022-07-18 Solid forms of berberine ursodeoxycholate and compositions and methods thereof

Country Status (10)

Country Link
US (3) US10959999B2 (enExample)
EP (2) EP4234568A3 (enExample)
JP (2) JP7685314B2 (enExample)
KR (2) KR20250017765A (enExample)
CN (1) CN108864077B (enExample)
AU (2) AU2018264384B2 (enExample)
CA (1) CA3062833A1 (enExample)
EA (1) EA201992607A1 (enExample)
ES (1) ES2988672T3 (enExample)
WO (1) WO2018205987A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108864077B (zh) * 2017-05-12 2020-05-22 深圳君圣泰生物技术有限公司 小檗碱有机酸盐的固体形式及其制备方法
CN110954645B (zh) * 2019-09-09 2020-09-29 山东琪康生物技术有限公司 一种高质量四黄止痢颗粒的检测方法
CN112851660B (zh) * 2019-11-12 2022-03-18 广东药科大学 含有小檗碱的酸-碱加成盐、其制备方法及其作为药物的用途
CN111920777A (zh) * 2020-09-18 2020-11-13 四川迪菲特药业有限公司 一种盐酸小檗碱片及其制备方法
KR102636847B1 (ko) * 2020-09-18 2024-02-19 경북대학교 산학협력단 티아민 유도체를 포함하는 이식편대숙주질환 예방 또는 치료용 약학적 조성물
WO2022083713A1 (en) * 2020-10-23 2022-04-28 Shenzhen Hightide Biopharmaceutical Ltd. Compositions of berberine ursodeoxycholate and methods thereof for treating fatty liver disease, diabetes and hyperlipidemia
US20230112845A1 (en) * 2020-10-23 2023-04-13 Shenzhen Hightide Biopharmaceutical Ltd. Compositions of berberine ursodeoxycholate and methods thereof for treating fatty liver disease, diabetes and hyperlipidemia
WO2022161468A1 (en) * 2021-01-28 2022-08-04 Shenzhen Hightide Biopharmaceutical Ltd. Compositions of berberine ursodeoxycholate and methods thereof for treating primary sclerosing cholangitis
US20230346803A1 (en) * 2021-01-28 2023-11-02 Shenzhen Hightide Biopharmaceutical Ltd. Compositions of berberine ursodeoxycholate and methods thereof for treating primary sclerosing cholangitis
WO2023088463A1 (en) * 2021-11-22 2023-05-25 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods of berberine ursodeoxycholate for modulating gut microbiome compositions
CN114716498B (zh) * 2022-01-20 2024-01-23 成都贝诺科成生物科技有限公司 一种高稳定性的失碳熊去氧胆酸小檗碱盐晶型及其制备方法
CN115477647A (zh) * 2022-10-26 2022-12-16 山西医科大学 小檗碱富马酸盐晶型及其制备方法和其组合物与应用
WO2024120452A1 (en) * 2022-12-07 2024-06-13 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods for prophylaxis and treatment of covid-19
CN118267476A (zh) * 2022-12-30 2024-07-02 深圳君圣泰生物技术有限公司 一种药物组合、药物组合物及其应用
AU2024222862A1 (en) * 2023-02-15 2025-09-11 Shenzhen Hightide Biopharmaceutical Ltd. Berberine tauroursodeoxycholate compositions and methods thereof
WO2024179570A1 (en) * 2023-03-01 2024-09-06 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods for treating severe hypertriglyceridemia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016015634A1 (en) * 2014-07-29 2016-02-04 Shenzhen Hightide Biopharmaceutical, Ltd. Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
CN105693805A (zh) * 2016-03-15 2016-06-22 合肥华方医药科技有限公司 一种胆酸类小檗碱偶合物的制备及医药用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005644A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxypropanamines
WO2007005643A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxyphenylpropanamines
EP1910322B1 (en) 2005-07-29 2012-09-05 Concert Pharmaceuticals Inc. Novel deuterated benzo [d][1,3]-dioxol derivatives as serotonin reuptake inhibitors
WO2007016361A2 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
CN102229636A (zh) * 2011-04-21 2011-11-02 东北林业大学 小檗碱9位酯键偶合胆酸的新衍生物及其制备方法
US9597337B2 (en) * 2014-04-04 2017-03-21 North American Biomedical Research Center Usa, Inc. Berberine-ursodeoxycholic acid conjugate for treating the liver
CN108864077B (zh) * 2017-05-12 2020-05-22 深圳君圣泰生物技术有限公司 小檗碱有机酸盐的固体形式及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016015634A1 (en) * 2014-07-29 2016-02-04 Shenzhen Hightide Biopharmaceutical, Ltd. Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
CN105693805A (zh) * 2016-03-15 2016-06-22 合肥华方医药科技有限公司 一种胆酸类小檗碱偶合物的制备及医药用途

Also Published As

Publication number Publication date
US20210251981A1 (en) 2021-08-19
KR20250017765A (ko) 2025-02-04
NZ759154A (en) 2024-07-26
US10959999B2 (en) 2021-03-30
JP7685314B2 (ja) 2025-05-29
EP4234568A3 (en) 2024-01-03
AU2022206685A1 (en) 2022-08-11
US20200188387A1 (en) 2020-06-18
EP3625229B1 (en) 2024-07-31
WO2018205987A1 (en) 2018-11-15
CN108864077B (zh) 2020-05-22
EP3625229C0 (en) 2024-07-31
CN108864077A (zh) 2018-11-23
EP3625229A4 (en) 2021-03-03
EP3625229B9 (en) 2024-10-09
US12138258B2 (en) 2024-11-12
KR102761338B1 (ko) 2025-02-04
US20250099456A1 (en) 2025-03-27
ES2988672T3 (es) 2024-11-21
AU2022206685B2 (en) 2024-05-02
AU2018264384A1 (en) 2019-12-12
EA201992607A1 (ru) 2020-06-29
JP2023104925A (ja) 2023-07-28
JP2020519654A (ja) 2020-07-02
EP3625229A1 (en) 2020-03-25
KR20230017930A (ko) 2023-02-07
EP4234568A2 (en) 2023-08-30
JP7728295B2 (ja) 2025-08-22
CA3062833A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
AU2022206685B2 (en) Solid forms of berberine ursodeoxycholate and compositions and methods thereof
TWI874490B (zh) 三苯化合物之新穎鹽類
EP3248983B1 (en) Crystal form a of obeticholic acid and preparation method therefor
AU2015330554B2 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
EP4177257B1 (en) Succinate of octahydrothienoquinoline compound, and crystals thereof
JP2025183212A (ja) ベルベリンウルソデオキシコール酸の固体形態ならびにその組成物および方法
HK40092147A (en) Solid forms of berberine ursodeoxycholate and compositions and methods thereof
WO2023150249A1 (en) Crystalline forms of an mcl-1 inhibitor
EA041133B1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
EP4631937A1 (en) Crystalline form or amorphous form of oxoisoindole-5-formamide compound or salt and solvate thereof
EP4553078A1 (en) 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one and crystal of salt thereof
WO2024143236A1 (ja) 酢酸エステル塩酸塩の結晶
HK40076742A (en) Novel salt of terphenyl compound
WO2014147641A2 (en) Sitagliptin pterostilbene phosphate salt, process for the preparation and pharmaceutical composition thereof
JPWO2005010019A1 (ja) 結晶形態の６−ｎ−ピリジルメチルアミノインドロカルバゾール化合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)